Compass Pathways Phase 3 COMP006 Data Review (NASDAQ:CMPS) 2026-07-07

Compass Pathways Phase 3 COMP006 Data Review (NASDAQ:CMPS) 2026-07-07

2026-07-07. The following slide deck was published by COMPASS Pathways plc in conjunction with this event.

Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?

On Tuesday, we covered Compass Pathways’ readout covering 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD): Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch. After our initial reporting published, the company shared more detailed slides (PDF) as well as prepared remarks on a webcast, which was followed by analyst Q& Source